Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Impact BioMedicalIBO +5.77%10 Buyback Yield % is 0.00 as of Aug. 14, 2026. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 724 Biotechnology companies, Impact BioMedical ranks worse than 138121.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Impact BioMedical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IBO vs ATYR, MCRB, TIL: Buyback Yield % Comparison
For the Biotechnology subindustry, Impact BioMedical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impact BioMedical Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Impact BioMedical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Impact BioMedical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impact BioMedical (IBO) has a Buyback Yield % of 0.00 as of Aug. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Impact BioMedical and its competitors. According to the industry distribution chart, Impact BioMedical ranks #999999 out of 724 companies in the Biotechnology industry.
Is Impact BioMedical's Buyback Yield % too high?
Impact BioMedical's current Buyback Yield % is 0.00. Based on the distribution chart, Impact BioMedical ranks #999999 out of 724 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's Buyback Yield % compare to ATYR and MCRB?
According to the Biotechnology industry distribution chart, Impact BioMedical ranks #999999 out of 724 companies for Buyback Yield %. This places Impact BioMedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Impact BioMedical and its competitors. Impact BioMedical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Impact BioMedical (IBO), the current Buyback Yield % is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score
Get the complete analysis for IBO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBO has been successfully added to your 
